Pharmacotherapy of addictions

Nature Reviews Drug Discovery

Volumn 1, Issue 9, 2002, Pages 710-726

  Kreek, Mary Jeanne ^a   LaForge, K Steven ^a   Butelman, Eduardo ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABECARNIL; ACAMPROSATE; ALCOHOL; AMANTADINE; AMFEBUTAMONE; AMLODIPINE; AMLODIPINE BESYLATE; AMLODIPINE PLUS BENAZEPRIL; BACLOFEN; BUPRENORPHINE; BUTORPHANOL; BUTORPHANOL TARTRATE; CABERGOLINE; CAPTOPRIL; CARNITINE; CELECOXIB; COCAINE; CYCLAZOCINE; DESIPRAMINE; DEXAMETHASONE; DEXTROMETHORPHAN; DIAMORPHINE; DISULFIRAM; LEVACETYLMETHADOL; METHADONE; NALMEFENE; NALOXONE; NALTREXONE; NICOTINE; OXAZEPAM; PROPRANOLOL; UBIQUINONE; UNINDEXED DRUG; MU OPIATE RECEPTOR; NARCOTIC ANTAGONIST;

DRUG APPROVAL; DRUG DEPENDENCE; DRUG EFFICACY; DRUG INDUSTRY; DRUG MECHANISM; DRUG RESEARCH; DRUG SCREENING; ENVIRONMENTAL FACTOR; HEALTH CARE COST; HEREDITY; HUMAN; LONG QT SYNDROME; MOUSE; NICOTINE REPLACEMENT THERAPY; NONHUMAN; PATHOLOGY; PRIORITY JOURNAL; RAT; REVIEW; WITHDRAWAL SYNDROME; ADDICTION; ALCOHOLISM; DRUG POTENTIATION; PSYCHOLOGICAL ASPECT;

ALCOHOLISM; BUPRENORPHINE; HUMANS; METHADONE; NALTREXONE; NARCOTIC ANTAGONISTS; RECEPTORS, OPIOID, MU; SUBSTANCE-RELATED DISORDERS;

EID: 0036719212     PISSN: 14741776     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrd897     Document Type: Review

References (194)

1. Dole, V. P., Nyswander, M. E. & Kreek, M. J. Narcotic blockade. Arch. Intern. Med. 118, 304-309 (1966).
2. Kreek, M. J. in Improving Drug Abuse Treatment: National Institute of Drug Abuse Research Monograph Series 106 (eds Pickens, R., Leukefeld, C. & Schuster, C. R.) 245-266 (US Govt Print. Off., Washington, DC, 1991).
3. Kreek, M. J. in Pharmacological Aspects of Drug Dependence: Toward an Integrated Neurobehavioral Approach (eds Schuster, C. R. & Kuhar, M. J.) 487-562 (Springer-Verlag, Berlin, 1996).
4. Kreek, M. J. in Pharmacological Aspects of Drug Dependence: Toward an Integrated Neurobehavioral Approach (eds Schuster, C. R. & Kuhar, M. J.) 563-598 (Springer-Verlag, Berlin, 1996).
5. Kreek, M. J. Opiates, opioids and addiction. Mol. Psych. 1, 232-254 (1996).
6. Kreek, M. J. Opioid receptors: Some perspectives from early studies of their role in normal physiology, stress responsivity and in specific addictive diseases. J. Neurochem. Res. 21, 1469-1488 (1996).
7. Kreek, M. J. in Problems of Drug Dependence, 1999; Proceedings of the 61st Annual Scientific Meeting of the College on Problems of Drug Dependence. National Institute of Drug Abuse Research Monograph Series Pub. No. (ADM) 00-4737,180 (ed. Harris, L. S.) 3-22 (US Govt Print. Off., Washington, DC, 2000).
8. Kreek, M. J. Methadone-related opioid agonist pharmacotherapy for heroin addiction: history, recent molecular and neurochemical research and the future in mainstream medicine. Ann. NY Acad. Sci. 909, 186-216 (2000).
9. Meltzer, H. Y. (ed.) Psychopharmacology: The Third Generation of Progress (New York, Raven Press, 1987).
10. Davis, K. L. (ed.) Psychopharmacology: The Fifth Generation of Progress (Lippincott Williams and Wilkins, Philadelphia) (in the press).
11. Kreek, M. J. & Koob, G. F. Drug dependence: stress and dysregulation of brain reward pathways. Drug Alcohol Depend. 51, 23-47 (1998).
12. Weiss, F. et al. Compulsive drug-seeking behavior and relapse. Neuroadaptation, stress, and conditioning factors. Ann. NY Acad. Sci. 937, 1-26 (2001).
13. Hyman, S. E. & Malenka, R. C. Addiction and the brain: the neurobiology of compulsion and its persistence. Nature Rev. Neurosci. 2, 695-703 (2001).
14. Nestler, E. J. Molecular basis of long-term plasticity underlying addiction. Nature Rev. Neurosci. 2, 119-128 (2001).
15. Weiss, F. & Porrino, L. J. Behavioral neurobiology of alcohol addiction: recent advances and challenges. J. Neurosci. 22, 3332-3337 (2002).
16. Johnson, S. W. & North, R. A. Opioids excite dopamine neurons by hyperpolarization of local interneurons. J. Neurosci. 12, 483-488 (1992).
17. Ritz, M. C., Lamb, R. J., Goldberg, S. R. & Kuhar, M. J. Cocaine receptors on dopamine transporters are related to self-administration of cocaine. Science 237, 1219-1223 (1987).
18. Rocha, B. A. et al. Cocaine self-administration in dopamine-transporter knockout mice. Nature Neurosci. 1, 132-137 (1998).
19. Sora, I. et al. Cocaine reward models: conditioned place preference can be established in dopamine- and in serotonin-transporter knockout mice. Proc. Natl Acad. Sci. USA 95, 7699-7704 (1998).
20. Sora, I. et al. Molecular mechanisms of cocaine reward: combined dopamine and serotonin transporter knockouts eliminate cocaine place preference. Proc. Natl Acad. Sci. USA 98, 5300-5305 (2001).
21. Matthes, H. W. D. et al. Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the μ-opioid receptor gene. Nature 383, 819-823 (1996).
22. Becker, A. et al. Morphine self-administration in μ-opioid receptor-deficient mice. Naunyn Schmiedebergs Arch. Pharmacol. 361, 584-590 (2000).
23. Sora, I. et al. Opiate receptor knockout mice define μ-receptor roles in endogenous nociceptive responses and morphine-induced analgesia. Proc. Natl Acad. Sci. USA 94, 1544-1549 (1997).
24. Pettit, H. O., Ettenberg, A., Bloom, F. E. & Koob, G. F. Destruction of dopamine in the nucleus accumbens selectively attenuates cocaine but not heroin self-administration in rats. Psychopharmacol. 84, 167-173 (1984).
25. Roberts, A. J. et al. μ-Opioid receptor knockout mice do not self-administer alcohol. J. Pharmacol. Exp. Ther. 293, 1002-1008 (2000).
26. Roberts, A. J. et al. Increased ethanol self-administration in δ-opioid receptor knockout mice. Alcohol Clin. Exp. Res. 25, 1249-1256 (2001).
27. Becker, A. et al. Rewarding effects of ethanol and cocaine in μ-opioid receptor-deficient mice. Naunyn Schmiedebergs Arch. Pharmacol. 365, 296-302 (2002).
28. Hurd, Y. L., Brown, E. E., Finlay, J. M., Fibiger, H. C. & Gerfen, C. R. Cocaine self-administration differentially alters mRNA expression of striatal peptides. Brain Res. Mol. Brain Res. 13, 165-170 (1992).
29. Spangler, R., Unterwald, E. M. & Kreek, M. J. 'Binge' cocaine administration induces a sustained increase of prodynorphin mRNA in rat caudate-putamen. Brain Res. Mol. Brain Res. 19, 323-327 (1993).
30. Daunais, J. B., Roberts, D. C. & McGinty, J. F. Cocaine self-administration increases preprodynorphin, but not c-fos, mRNA in rat striatum. Neuroreport 4, 543-546 (1993).
31. Unterwald, E. M., Rubenfeld, J. M. & Kreek, M. J. Repeated cocaine administration upregulates κ and μ, but not δ, opioid receptors. NeuroReport 5, 1613-1616 (1994).
32. Unterwald, E. M., Kreek, M. J. & Cuntapay, M. The frequency of cocaine administration impacts cocaine-induced receptor alterations. Brain Res. 900, 103-109 (2001).
33. Spangler, R. et al. Prodynorphin, proenkephalin and κ-opioid receptor mRNA responses to acute 'binge' cocaine. Mol. Brain Res. 44, 139-142 (1997).
34. Wang, X. M. et al. Acute intermittent morphine increases preprodynorphin and κ-opioid receptor mRNA levels in the rat brain. Mol. Brain Res. 66, 184-187 (1999).
35. Claye, L. H., Maisonneuve, I. M., Yu, J., Ho, A. & Kreek, M. J. Local perfusion of dynorphin A 1-17 reduces extracellular dopamine levels in the nucleus accumbens. NIDA Res. Monogr. 174, 113 (1997).
36. Zimprich, A. et al. An allelic variation in the human prodynorphin gene promoter alters stimulus-induced expression. J. Neurochem. 74, 472-477 (2000).
37. Chen, A. C. H. et al. Potentially functional polymorphism in the promoter region of prodynorphin gene may be associated with protection against cocaine dependence or abuse. Am. J. Med. Genet. 114, 429-435 (2002).
38. Swanson, C. J, Baker, D. A., Carson, D., Worley, P. F. & Kalivas, P. W. Repeated cocaine administration attenuates group I metabotropic glutamate receptor-mediated glutamate release and behavioral activation: a potential role for Homer. Neuroscience 21, 9043-9052 (2001).
39. Cornish, J. L. & Kalivas, P. W. Cocaine sensitization and craving: differing roles for dopamine and glutamate in the nucleus accumbens. J. Addict. Dis. 20, 43-54 (2001).
40. McFarland, K. & Kalivas, P. W. The circuitry mediating cocaine-induced reinstatement of drug-seeking behavior. J. Neuroscience 21, 8655-8663 (2001).
41. Paul, M., Dewey, S. L., Gardner, E. L., Brodie, J. D. & Ashby, C. R. Jr. γ-Vinyl GABA (GVG) blocks expression of the conditioned place preference response to heroin in rats. Synapse 41, 219-220 (2001).
42. Gerasimov, M. R. et al. GABAergic blockade of cocaine-associated cue-induced increases in nucleus accumbens dopamine. Eur. J. Pharmacol. 414, 205-209 (2001).
43. Gerasimov, M. R. et al. γ-Vinyl GABA inhibits methamphetamine, heroin, or ethanol-induced increases in nucleus accumbens dopamine. Synapse 34, 11-19 (1999).
44. Roberts, D. C., Andrews, M. M. & Vickers, G. J. Baclofen attenuates the reinforcing effects of cocaine in rats. Neuropsychopharmacol. 15, 417-423 (1996).
45. B agonist baclofen modifies cocaine self-administration in rats. Behav. Pharmacol. 9, 195-206 (1998)
46. Ling, W., Shoptaw, S. & Majewska, D. Baclofen as a cocaine anti-craving medication: a preliminary clinical study. Letter to the editor. Neuropsychopharmacol. 18, 403-404 (1998).
47. Kreek, M. J. Medical safety and side effects of methadone in tolerant individuals. JAMA 223, 665-668 (1973).
48. Kreek, M. J. in Neuropsychopharmacology: The Fifth Generation of Progress (ed. Davis, K. L.) 1491-1506 (Lippincott Williams and Wilkins, Philadelphia, 2002).
49. Mathieu-Kia, A. M., Kellogg, S. H., Butelman, E. R. & Kreek, M. J. Nicotine addiction: insights from recent animal studies. Psychopharmacol. 162, 102-118 (2002).
50. Dole, V. P. & Nyswander, M. E. A medical treatment for diacetylmorphine (heroin) addiction. JAMA 193, 646 (1965).
51. Rettig, R. A. & Yarmolinsky, A. (eds) Federal Regulation of Methadone Treatment (National Academy Press, Washington DC, 1995).
52. Kreek, M. J. & Vocci, F. J. The efficacy of methadone and levomethadyl acetate (LAAM). J. Subst. Abuse Treat. (in the press).
53. McLellan, A. T., Arndt, I. O., Metzger, D. S., Woody, G. E. & O'Brien, C. P. The effects of psychosocial services in substance treatment. JAMA 269, 1953-1959 (1993).
54. 35S]GTPγS binding in mMOR-CHO cells and rat thalamus. J. Pharmacol. Exp. Ther. 285, 496-505 (1998).
55. L-isomers of methadone bind to the non-competitive site on the N-methyl-D-aspartate (NMDA) receptor in rat forebrain and spinal cord. Neurosci. Lett. 223, 1-4 (1997).
56. D-Methadone blocks morphine tolerance and N-methyl-D-aspartate (NMDA)-induced hyperalgesia. J. Pharmacol. Exp. Ther. 289, 1048-1053 (1999).
57. Keith, D. E. et al. μ-Opioid receptor internalization: opiate drugs have differential effects on a conserved endocytic mechanism in vitro and in the mammalian brain. Mol. Pharmacol. 53, 377-384 (1998).
58. Yu, Y. et al. μ-Opioid receptor phosphorylation, desensitization, and ligand efficacy. J. Biol. Chem. 272, 28869-28874 (1997).
59. Altshuler, H. L. Behavioral methods for the assessment of alcohol tolerance and dependence. Drug Alcohol Depend. 4, 333-346 (1979).
60. Volpicelli, J. R., Alterman, A. I., Hayahida, M. & O'Brien, C. P. Naltrexone in the treatment of alcohol dependence. Arch. Gen. Psychiatry 49, 879-880 (1992).
61. O'Malley, S. S. et al. Naltrexone and coping skills therapy for alcohol dependence: a controlled study. Arch. Gen. Psychiatry 49, 881 (1992).
62. Mason, B. J. et al. A double-blind, placebo-controlled pilot study to evaluate the efficacy and safety of oral nalmefene HCl for alcohol dependence. Alcohol Clin. Exp. Res. 18, 1162-1167 (1994).
63. O'Malley, S. S., Croop, R. S., Wroblewski, J. M., Labriola, D. F. & Volpicelli, J. R. Naltrexone in the treatment of alcohol dependence: a combined analysis of two trials. Psychiatr. Ann. 25, 681-688 (1995).
64. Doty, P. & de Wit, H. Effects of naltrexone pretreatment on the subjective and performance effects of ethanol in social drinkers. Behav. Pharmacol. 6, 386-394 (1995).
65. Volpicelli, J. R., Rhines, K. C., Volpicelli, L. A., Alterman, A. I. & O'Brien, C. P. Naltrexone and alcohol dependence: role of subject compliance. Arch. Gen. Psychiatry 54, 737-742 (1997).
66. Mason, B. J., Salvato, F. R., Williams, L. C., Ritvo, E. C. & Cutler, R. B. A double-blind placebo-controlled study of oral nalmefene for alcohol dependence. Arch. Gen. Psychiatry 56, 719-724 (1999).
67. King, A. C., Batel, P. & Kreek, M. J. Recent alcoholism treatment research: ethical issues of implementation into clinical practice. Adv. Bioethics 3, 257-286 (1997).
68. King, A. C. et al. Hypothalamic-pituitary-adrenocortical (HPA) axis response and biotransformation of oral naltrexone: Preliminary examination of relationship to family history of alcoholism. Neuropsychopharmacol. 26, 778-788 (2002).
69. O'Malley, S. S., Krishnan-Sarin, S., Farren, C., Sinha, R. & Kreek, M. J. Naltrexone decreases craving and alcohol self-administration in alcohol dependent subjects and activates the hypothalamo-pituitary-adrenocortical axis. Psychopharmacol. 160, 19-29 (2002).
70. Bond, C. et al. Single nucleotide polymorphism in the human μ-opioid receptor gene alters β-endorphin binding and activity: possible implications for opiate addiction. Proc. Natl Acad. Sci. USA 95, 9608-9613 (1998).
71. LaForge, K. S., Yuferov, V. & Kreek, M. J. Opioid receptor and peptide gene polymorphisms: potential implications for addictions. Eur. J. Pharmacol. 410, 249-268 (2000).
72. LaForge, K. S. et al. Symposium XIII: allelic polymorphisms of human opioid receptors: functional studies: genetic contributions to protection from, or vulnerability to, addictive diseases. NIDA Res. Monograph. 180, 47-50 (2000).
73. Wand, G. S. et al. The μ-opioid receptor gene polymorphism (A118G) alters HPA axis activation induced by opioid receptor blockade. Neuropsychopharmacol. 26, 106-114 (2002).
74. Kampman, K. M. et al. Effectiveness of propranolol for cocaine dependence treatment may depend on cocaine withdrawal symptom severity. Drug Alcohol. Depend. 63, 69-78 (2001).
75. Major, L. F., Ballenger, J. C., Goodwin, F. K. & Brown, G. L. Cerebrospinal fluid homovanillic acid in male alcoholics: effects of disulfiram. Biol. Psychiatry 12, 635-642 (1977).
76. Musacchio, J. M., Goldstein, M., Anagnoste, B., Poch, G. & Kopin, I. J. Inhibition of dopamine-heta-hydroxylase by disulfiram in vivo. J. Pharmacol. Exp. Ther. 152, 56-61 (1966).
77. McCance-Katx, E. F., Kosten, T. R. & Jatlow, P. Disulfiram effects on acute cocaine administration. Drug Alcohol. Depend. 52, 27-39 (1998).
78. George, T. P. et al. Disulfiram versus placebo for cocaine dependence in buprenorphine-maintained subjects: a preliminary trial. Biol. Psychiatry 47, 1080-1086 (2000).
79. Carroll, K. M. et al. One-year follow-up of disulfiram and psychotherapy for cocaine-alcohol users: sustained effects of treatment. Addiction 95, 1335-1349 (2000).
80. Petrakis, I. L. et al. Disulfiram treatment for cocaine dependence in methadone-maintained opioid addicts. Addiction 95, 219-228 (2000).
81. Littleton, J. Acamprosate in alcohol dependence: how does it work? Addiction 90, 1179-1188 (1995).
82. Verbank, P. M. The pharmacological treatment of alcoholism: from basic science to clinical medicine. Alcohol Alcohol. 30, 757-764 (1995).
83. Paille, F. M. et al. Double-blind randomized mulitcentre trial of acamprosate in maintaining abstinence from alcohol. Alcohol Alcohol. 30, 239-247 (1995).
84. Batel, P. The treatment of alcoholism in France. Drug Alcohol Depend. 39, S15-S21 (1995).
85. Chick, J. Acamprosate as an aid in the treatment of alcoholism. Alcohol Alcohol. 30, 785-787 (1995).
86. Whitworth, A. B. et al. Comparison of acamprosate and placebo in long-term treatment of alcohol dependence. Lancet 347, 1438-1442 (1996).
87. Sass, H., Soyka, M., Mann, K. & Zieglgansberger, W. Relapse prevention by acamprosate. Results from a placebo-controlled study on alcohol dependence. Arch. Gen. Pscyhiatry 53, 673-680 (1996).
88. Comer, S. D. et al. Depot naltrexone: long-lasting antagonism of the effects of heroin in humans. Pyschopharmacol. 159, 351-360 (2002).
89. 18F]cyclofoxy in long-term methadone-treated former heroin addicts. J. Pharmacol. Exp. Ther. 295, 1070-1076 (2000).
90. Schluger, J. H. et al. Nalmefene causes greater hypothalamic-pituitary-adrenal axis activation than naloxone in normal volunteers: implications for the treatment of alcoholism. Alcohol. Clin. Exp. Res. 22, 1430-1436 (1998).
91. Borg, L., Broe, D. M., Ho, A. & Kreek, M. J. Cocaine abuse sharply reduced in an effective methadone maintenance program. J. Addict. Dis. 18, 63-75 (1999).
92. Unterwald, E. M., Horne-King, J. & Kreek, M. J. Chronic cocaine alters brain μ-opioid receptors. Brain Res. 584, 314-318 (1992).
93. Zubieta, J. K. et al. Increased μ-opioid receptor binding detected by PET in cocaine-dependent men is associated with cocaine craving. Nature Med. 2, 1225-1229 (1996).
94. Azaryan, A. V., Clock, B. J. & Cox, B. M. Transient upregulation of μ-opioid receptor mRNA in nucleus accumbens during chronic cocaine administration. FASEB J. 10, A448 (1996).
95. Yuferov, V. et al. Acute 'binge' cocaine increases μ-opioid receptor mRNA levels in areas of the rat mesolimbic mesocortical dopamine system. Brain Res. Bull. 48, 109-112 (1999).
96. Kreek, M. J. et al. Circadian rhythms and levels of β-endorphin, ACTH, and cortisol during chronic methadone maintenance treatment in humans. Life Sci. 33, 409-411 (1983).
97. Kreek, M. J. et al. ACTH, cortisol and β-endorphin response to metyrapone testing during chronic methadone maintenance treatment in humans. Neuropeptides 5, 277-278 (1984).
98. Schluger, J., Bodner, G., Gunduz, M., Ho, A. & Kreek, M. J. in Problems of Drug Dependence, 1997; Proceedings of the 59th Annual Scientific Meeting of the College on Problems of Drug Dependence. National Institute of Drug Abuse Research Monograph Series (ed. Harris, L. S.) DHHS Pub. No. ADM 98-4305, 178:105 (US Govt Print. Off., Washington DC, 1998).
99. Schluger, J. H., Borg, L., Ho, A. & Kreek, M. J. Altered HPA axis responsivity to metyrapone testing in methadone maintained former heroin addicts with ongoing cocaine addiction. Neuropsychopharmacol. 24, 568-575 (2001).
100. Kreek, M. J. Opiate and cocaine addictions: challenge for pharmacotherapies. Pharm. Biochem. Behav. 57, 551-569 (1997).
101. Kreek, M. J. in Proc. Fourth National Conference on Methadone Treatment. National Association for the Prevention of Addiction to Narcotics (NAPAN)-NIMH 171-174 (1972).
102. Kreek, M. J. Medical complications in methadone patients. Ann. NY Acad. Sci. 311, 110-134 (1978).
103. Zhou, Y. et al. Hypothalamic-pituitary-adrenal activity and POMC mRNA levels in the hypothalamus and pituitary of the rat are differentially modulated by acute intermittent morphine with or without water restriction stress. J. Endocrinol. 154, 261-267 (1999).
104. Zhou, Y. et al. Corticotropin-releasing factor and CRF-R1 mRNAs in rat brain and pituitary during 'binge' pattern cocaine administration and chronic withdrawal. J. Pharmacol. Exp. Ther. 279, 351-358 (1996).
105. Zhou, Y. et al. Reduced hypothalamic POMC and anterior pituitary CRF1 receptor mRNA levels after acute, but not chronic, daily 'binge' intragastric alcohol administration. Alcohol. Clin. Exp. Res. 24, 1575-1582 (2000).
106. Zhou, Y. et al. Steady-state methadone in rats does not change mRNA levels of corticotropin-releasing factor, its pituitary receptor or proopiomelanocortin. Eur. J. Pharmacol. 315, 31-35 (1996).
107. Spangler, R., Zhou, Y, Schlussman, S. D., Ho, A, & Kreek, M. J. Behavioral stereotypies induced by 'binge' cocaine administration are independent of drug-induced increases in corticosterone levels. Behav. Brain Res. 86, 201-204 (1997).
108. Zhou, Y. et al. Effects of chronic 'binge' cocaine administration on plasma ACTH and corticosterone levels in mice deficient in DARPP-32. Neuroendocrinology 70, 196-199 (1999).
109. 1 dopamine receptor blockade. Mol. Brain Res. 94, 112-118 (2001).
110. Mendelson, J. H. et al. Cocaine tolerance: behavioral, cardiovascular, and neuroendocrine function in men. Neuropharmacol. 18, 263-271 (1998).
111. Kennedy, J. A., Hartman, N., Sbriglio, R., Khuri, E. & Kreek, M. J. Metyrapone-induced withdrawal symptoms. Br J. Addict. 85, 1133-1140 (1990).
112. Culpepper-Morgan, J. A. et al. Treatment of opioid induced constipation with oral naloxone: a pilot study. Clin. Pharm. Ther. 23, 90-95 (1992).
113. Culpepper-Morgan, J. A. & Kreek, M. J. HPA axis hypersensitivity to naloxone in opioid dependence: a case of naloxone induced withdrawal. Metabolism 46, 130-134 (1997).
114. Rosen, M. I. et al. Reliability of sequential naloxone challenge tests. Am. J. Drug Alcohol Abuse 214, 453-467 (1995).
115. Volavka, J. et al. Naloxone increases ACTH and cortisol in man. N. Engl. J. Med. 300, 1056-1057 (1979).
116. Cohen, M. R., Cohen, R. M., Pickar, D., Weingartner, H. & Murphy, D. L. High-dose naloxone infusions in normals. Dose-dependent behavioral, hormonal, and physiological responses. Arch. Gen. Psychiat. 40, 613-619 (1983).
117. Kreek, M. J., Schneider, B. S., Raghunath, J. & Plevy, S. in Abstracts of the Seventh International Congress of Endocrinology, Excerpta Medica. Int. Congress Series 652 848 (Oxford-Princeton, Amsterdam, 1984).
118. Kosten, T. R., Kreek, M. J., Raghunath, J. & Kleber, H. D. Cortisol levels during chronic naltrexone maintenance treatment in ex-opiate addicts. Biol. Psychiatry 21, 217-220 (1986).
119. Kosten, T. R., Kreek, M. J., Raghunath, J. & Kleber, H. D. A preliminary study of β-endorphin during chronic naltrexone maintenance treatment in ex-opiate addicts. Life Sci. 39, 55-59 (1986).
120. Kosten, T. R., Morgan, C. & Kreek, M. J. β-Endorphin levels during heroin, methadone, duprenorphine and naloxone challenges: preliminary findings. Biol. Psychiatry 32, 523-528 (1992).
121. Sillaber, I. et al. Enhanced and delayed stress-induced alcohol drinking mice lacking functional CHR1 receptors. Science 296, 931-933 (2002).
122. Di Chiara, G. & Imperato, A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc. Natl Acad. Sci. USA 85, 5274-5278 (1988).
123. Spanagel, R., Herz, A. & Shippenberg, T. S. Opposing tonically active endogenous opioid systems modulate the mesolimbic dopaminergic pathway. Proc. Natl Acad. Sci. USA 89, 2046-2050 (1992).
124. Metzger, R. R., Hanson, G. R., Gibb, J. W. & Fleckenstein, A. E. 3-4-Methylenedioxymethamphetamine-induced acute changes in dopamine transporter function. Eur. J. Pharmacol. 349, 205-210 (1998).
125. Bozarth, M. A. & Wise, R. A. Neural substrates of opiate reinforcement. Prog. Neuropsychopharmacol. Biol. Psychiatry 7, 569-575 (1983).
126. Rassnick, S., Pulvirenti, L. & Koob, G. F. Oral ethanol self-administration in rats is reduced by the administration of dopamine and glutamate receptor antagonists into the nucleus accumbens. Psychopharmacol. (Berl.) 109, 92-98 (1992).
127. Negus, S. S., Mello, N. K., Lamas, X. & Mendelson, J. H. Acute and chronic effects of flupenthixol on the discriminative stimulus and reinforcing effects of cocaine in rhesus monkeys. J. Pharmacol. Exp. Ther. 278, 879-890 (1996).
128. Sherer, M. A., Kumor, K. M. & Jaffe, J. H. Effects of intravenous cocaine are partially attenuated by haloperidol. Psychiatry Res. 27, 117-125 (1989).
129. Ohuoha, D. C., Maxwell, J. A., Thomson, L. E., Cadet, J. L. & Rothman, R. B. Effect of dopamine receptor antagonists on cocaine subjective effects: a naturalistic case study. J. Subst. Abuse Treat. 14, 249-258 (1997).
130. Evans, S. M. et al. Effect of flupenthixol on subjective and cardiovascular responses to intravenous cocaine in humans. Drug Alcohol Depend. 64, 271-283 (2001).
131. Haney, M., Ward, A. S., Foltin, R. W. & Fischman, M. W. Effects of ecopipam, a selective dopamine D1 antagonist, on smoked cocaine self-administration by humans. Psychopharmacol. (Berl.) 155, 330-337 (2001).
132. Pilla, M. et al. Selective inhibition of cocaine-seeking behaviour by a partial dopamine D3 receptor agonist. Nature 400, 371-375 (1999).
133. Platt, D. M., Rowlett, J. K. & Spealman, R. D. Modulation of cocaine and food self-administration by low- and high-efficacy D1 agonists in squirrel monkeys. Psychopharmacol. (Berl.) 157, 208-216 (2001).
134. Mutschler, N. H. & Bergman, J. Effects of chronic administration of the D(1) receptor partial agonist SKF 77434 on cocaine self-administration in rhesus monkeys. Psychopharmacol. (Berl.) 160, 362-370 (2002).
135. Caine, S. B., Negus, S. S., Mello, N. K. & Bergman, J. Effects of dopamine D(1-like) and D(2-like) agonists in rats that self-administer cocaine. J. Pharmacol. Exp. Ther. 291, 353-360 (1999).
136. Ranaldi, R., Wang, Z. & Woolverton, W. L. Reinforcing effects of D2 dopamine receptor agonists and partial agonists in rhesus monkeys. Drug Alcohol Depend. 64, 209-217 (2001).
137. Sinnott, R. S., Mach, R. H. & Nader, M. A. Dopamine D2/D3 receptors modulate cocaine's reinforcing and discriminative stimulus effects in rhesus monkeys. Drug Alcohol Depend. 54, 97-110 (1999).
138. Malcolm, R., Hutto, B. R., Phillips, J. D. & Ballenger, J. C. Pergolide mesylate treatment of cocaine withdrawal. J. Clin. Psychiatry 52, 39-40 (1991).
139. Eiler, K., Schaefer, M. R., Salstrom, D. & Lowery, R. Double-blind comparison of bromocriptine and placebo in cocaine withdrawal. Am. J. Drug Alcohol Abuse 21, 65-79 (1995).
140. Levin, F. R. et al. Pergolide mesylate for cocaine abuse: a controlled preliminary trial. Am. J. Addict. 8, 120-127 (1999).
141. Haney, M., Collins, E. D., Ward, A. S., Foltin, R. W. & Fischman, M. W. Effect of a selective dopamine D1 agonist (ABT-431) on smoked cocaine self-administration in humans. Psychopharmacol. (Berl.) 143, 102-110 (1999).
142. Ritz, M. C., Cone, E. J. & Kuhar, M. J. Cocaine inhibition of ligand binding at dopamine, noradrenaline and serotonin transporters: a structure-activity study. Life Sci. 46, 635-648 (1990).
143. Kolar, A. F. et al. Treatment of cocaine dependence in methadone maintenance clients: a pilot study comparing the efficacy of desipramine and amantadine. Int. J. Addict. 27, 849-868 (1992).
144. Arndt, I. O., Dorozynsky, L., Woody, G. E., McLellan, A. T. & O'Brien, C. P. Desipramine treatment of cocaine dependence in methadone-maintained patients. Arch. Gen. Psychiatry 49, 888-893 (1992).
145. Walsh, S. L., Preston, K. L., Sullivan, J. T., Fromme, R. & Bigelow, G. E. Fluoxetine alters the effects of intravenous cocaine in humans. J Clin. Psychopharmacol. 14, 396-407 (1994).
146. Margolin, A. et al. A multicenter trial of bupropion for cocaine dependence in methadone-maintained patients. Drug Alcohol Depend. 40, 125-131 (1995).
147. Nunes, E. V. et al. Imipramine treatment of cocaine abuse: possible boundaries of efficacy. Drug Alcohol Depend. 39, 185-195 (1995).
148. Levin, F. R., Evans, S. M., McDowell, D. M. & Kleber, H. D. Methylphenidate treatment for cocaine abusers with adult attention-deficit/hyperactivity disorder: a pilot study. J. Clin. Psychiatry 59, 300-305 (1998).
149. Roache, J. D., Grabowski, J., Schmitz, J. M., Creson, D. L. & Rhoades, H. M. Laboratory measures of methylphenidate effects in cocaine-dependent patients receiving treatment. J. Clin. Psychopharmacol. 20, 61-68 (2000).
150. Villemagne, V. L. et al. Doses of GBR12909 that suppress cocaine self-administration in non-human primates substantially occupy dopamine transporters as measured by [11C] WIN35,428 PET scans. Synapse 32, 44-50 (1999).
151. Ranaldi, R., Anderson, K. G., Carroll, F. I. & Woolverton, W. L. Reinforcing and discriminative stimulus effects of RTI 111, a 3-phenyltropane analog, in rhesus monkeys: interaction with methamphetamine. Psychopharmacol. (Berl.) 153, 103-110 (2000).
152. Cook, C. D., Carroll, F. I. & Beardsley, P. M. RTI 113, a 3-phenyltropane analog, produces long-lasting cocaine-like discriminative stimulus effects in rats and squirrel monkeys. Eur. J. Pharmacol. 442, 93-98 (2002).
153. Wilcox, K. M. et al. Self-administration of cocaine and the cocaine analog RTI-113: relationship to dopamine transporter occupancy determined by PET neuroimaging in rhesus monkeys. Synapse 43, 713-85 (2002).
154. Di Chiara, G. & Imperato, A. Opposite effects of μ and κ-opiate agonists on dopamine release in the nucleus accumbens and in the dorsal caudate of freely moving rats. J. Pharmacol. Exp. Ther. 244, 1067-1080 (1988).
155. Spanagel, R., Herz, A. & Shippenberg, T. S. The effects of opioid peptides on dopamine release in the nucleus accumbens: an in vivo microdialysis study. J. Neurochem. 55, 1734-1740 (1990).
156. Maisonneuve, I. M., Archer, S. & Glick, S. D. U50,488, a κ-opioid receptor agonist, attenuates cocaine-induced increases in extracellular dopamine in the nucleus accumbens of rats. Neurosci. Lett. 181, 57-60 (1994).
157. Bals-Kubik, R., Ableitner, A., Herz, A. & Shippenberg, T. S. Neuroanatomical sites mediating the motivational effects of opioids as mapped by the conditioned place preference paradigm in rats. J. Pharmacol. Exp. Ther. 264, 489-495 (1993).
158. Glick, S. D., Maisonneuve, I. M., Raucci, J. & Archer, S. κ-Opioid inhibition of morphine and cocaine self-administration in rats. Brain Res. 681, 147-152 (1995).
159. Emmerson, P. J., Liu, M. R., Woods, J. H. & Medzihradsky, F. Binding affinity and selectivity of opioids at μ, δ and κ receptors in monkey brain membranes. J. Pharmacol. Exp. Ther. 271, 1540-1547 (1994).
160. Raynor, K. et al. Pharmacological characterization of the cloned κ-, δ-, and μ-opioid receptors. Mol. Pharmacol. 48, 330-334 (1994).
161. France, C. P. & Gerak, L. R. Behavioral effects of 6-methylene naltrexone (nalmefene) in rhesus monkeys. J. Pharmacol. Exp. Ther. 270, 992-999 (1994).
162. Ko, M. C., Butelman, E. R., Traynor, J. R. & Woods, J. H. Differentiation of κ-opioid agonist-induced antinociception by naltrexone apparent pA2 analysis in rhesus monkeys. J. Pharmacol. Exp. Ther. 285, 518-526 (1998).
163. Negus, S. S., Mello, N. K., Portoghese, P. S. & Lin, C. E. Effects of κ opioids on cocaine self-administration by rhesus monkeys. J. Pharmacol. Exp. Ther. 282, 44-55 (1997).
164. Kuzmin, A. V., Gerrits, M. A. & van Ree, J. M. κ-Opioid receptor blockade with nor-binaltorphimine modulates cocaine self-administration in drug-naive rats. Eur. J. Pharmacol. 358, 197-202 (1998).
165. Portoghese, P. S., Nagase, H., Lipkowski, A. W., Larson, D. L. & Takemori, A. E. Binaltorphimine-related bivalent ligands and their κ-opioid receptor antagonist selectivity. J. Med. Chem. 31, 836-841 (1988).
166. Negus, S. S., Mello, N. K., Linsenmayer, D. C., Jones, R. C. & Portoghese, P. S. κ-Antagonist effcts of the novel κ-antagonist 5'-guanidinonaltrindole (GNTI) in an assay of schedule controlled behavior. Psychopharmacol. (in the press).
167. Butelman, E. R., Negus, S. S., Ai, Y., de Costa, B. R. & Woods, J. H. κ-Opioid antagonist effects of systemically administered nor-binaltorphimine in a thermal antinociception assay in rhesus monkeys. J. Pharmacol. Exp. Ther. 267, 1269-1276 (1993).
168. Broadbear, J. H., Negus, S. S., Butelman, E. R., de Costa, B. R. & Woods, J. H. Differential effects of systemically administered nor-binaltorphimine (nor-BNI) on κ-opioid agonists in the mouse writhing assay. Psychopharmacol. (Berl.) 115, 311-319 (1994).
169. Neumeyer, J. L. et al. Mixed κ agonists, and μ agonists/antagonists as potential pharmacotherapeutics for cocaine abuse: synthesis and opioid receptor binding affinity of N-substituted derivatives of morphinan. Bioorg. Med. Chem. Lett. 11, 2735-2740 (2001).
170. Toll, L. et al. Standard binding and functional assays related to medications development division testing for potential cocaine and opiate narcotic treatment medications. NIDA Res. Monog. 178, 440-466 (1997).
171. France, C. P., Medzihradsky, F. & Woods, J. H. Comparison of κ opioids in rhesus monkeys: behavioral effects and receptor binding affinities. J. Pharmacol. Exp. Ther. 268, 47-58 (1994).
172. Dykstra, L. A. Butorphanol, levallorphan, nalbuphine and nalorphine as antagonists in the squirrel monkey. J. Pharmacol. Exp. Ther. 254, 248-252 (1990).
173. Archer, S., Glick, S. D. & Bidlack, J. M. Cyclazocine revisited. Neurochem. Res. 21, 1369-1373 (1996).
174. Glick, S. D., Visker, K. E. & Maisonneuve, I. M. Effects of cyclazocine on cocaine self-administration in rats. Eur. J. Pharmacol. 357, 9-14 (1998).
175. Gear, R. W. et al. The κ opioid nalbuphine produces gender- and dose-dependent analgesia and antianalgesia in patients with postoperative pain. Pain 83, 339-348 (1999).
176. Walsh, S. L., Geter-Douglas, B., Strain, E. C. & Bigelow, G. E. Enadoline and butorphanol: evaluation of κ-agonists on cocaine pharmacodynamics and cocaine self-administration in humans. J. Pharmacol. Exp. Ther. 299, 147-158 (2001).
177. Remmers, A. E. et al. Opioid efficacy in a C6 glioma cell line stably expressing the human κ opioid receptor. J. Pharmacol. Exp. Ther. 288, 827-833 (1999).
178. Vivian, J. A. et al. κ-Opioid receptor effects of butorphanol in rhesus monkeys. J. Pharmacol. Exp. Ther. 290, 259-265 (1999).
179. Heidbreder, C. A., Goldberg, S. R. & Shippenberg, T. S. The κ-opioid receptor agonist U-69593 attenuates cocaine-induced behavioral sensitization in the rat. Brain Res. 616, 335-338 (1993).
180. Shippenberg, T. S., LeFevour, A. & Heidbreder, C. κ-Opioid receptor agonists prevent sensitization to the conditioned rewarding effects of cocaine. J. Pharmacol. Exp. Ther. 276, 548-554 (1996).
181. Mello, N. K. & Negus, S. S. Effects of κ-opioid agonists on cocaine- and food-maintained responding by rhesus monkeys. J. Pharmacol. Exp. Ther. 286, 812-824 (1998).
182. Dykstra, L. A., Gmerek, D. E., Winger, G. & Woods, J. H.
183. Pfeiffer, A., Brantl, V., Herz, A. & Emrich, H. M. Psychotomimesis mediated by κ opiate receptors. Science 233, 774-776 (1986).
184. Ur, E., Wright, D. M., Bouloux, P. M. & Grossman, A. The effects of spiradoline (U-62066E), a κ-opioid receptor agonist, on neuroendocrine function in man. Br. J. Pharmacol. 120, 781-784 (1997).
185. Gmerek, D. E., Dykstra, L. A. & Woods, J. H. κ-Opioids in rhesus monkeys. III. Dependence associated with chronic administration. J. Pharmacol. Exp. Ther. 242, 428-436 (1987).
186. Kreek, M. J., Schluger, J., Borg, L., Gunduz, M. & Ho, A. Dynorphin A1-13 causes elevation of serum levels of prolactin through an opioid receptor mechanism in humans: gender differences and implications for modulations of dopaminergic tone in the treatment of addictions. J. Pharmacol. Exp. Ther. 288, 260-269 (1999).
187. King, A. C., Ho, A., Schluger, J., Borg, L. & Kreek, M. J. Acute subjective effects of dynorphin A(1-13) infusion in normal healthy subjects. Drug Alcohol Depend. 54, 87-90 (1999).
188. Nakazawa, T. et al. Analgesia produced by E-2078, a systemically active dynorphin analog, in mice. J. Pharmacol. Exp. Ther. 252, 1247-1254 (1990).
189. Yu, J., Butelman, E. R., Woods, J. H., Chait, B. T. & Kreek, M. J. Dynorphin A (1-8) analog, E-2078, is stable in human and rhesus monkey blood. J. Pharmacol. Exp. Ther. 280, 1147-1151 (1997).
190. Butelman, E. R., Harris, T. J. & Kreek, M. J. Effects of E-2078, a stable dynorphin A(1-8) analog, on sedation and serum prolactin levels in rhesus monkeys. Psychopharmacol. (Berl.) 147, 73-80 (1999).
191. Ohnishi, A. et al. Aquaretic effect of the stable dynorphin-A analog E2078 in the human. J. Pharmacol. Exp. Ther. 270, 342-347 (1994).
192. Bergen, A. W., et al. μ-Opioid receptor gene variants: lack of association with alcohol dependence. Mol. Psychiatry 2, 490-494 (1997).
193. Szeto, C. Y., Tang, N. L., Lee, D. T. & Stadlin, A. Association between μ-opioid receptor gene polymorphisms and Chinese heroin addicts. Neuroreport 12, 1103-1106 (2001).
194. Mark, T. L., Woody, G. E., Juday, T. & Kleber, H. D. The economic costs of heroin addiction in the United States. Drug Alcohol Depend. 61, 195-206 (2001).